Fig. 2.

APX005M agonist activity requires FcR-mediated crosslinking. a Activation of B cells after 48 h by APX005M intact (green squares) or APX005M F(ab’)2 fragments (gray circles) as measured by MFI of CD86 expression. Data are representative of two donors. b Binding of APX005M (green squares), APX005 (black circles) and isotype control (open circle) to human FcγRIIb—expressing CHO cells. c Activation of B cells by APX005M (green squares), APX005 (black circles) and isotype control (open circle) for 48 h as measured by MFI of CD86 expression. Data are representative of three donors. d NK cell-mediated ADCC activity of APX005M (green squares) and APX005 (black circles) on human Daudi B cells. Rituximab (red triangles) and human IgG1 isotype control (open circles) were used as controls. All conditions were performed in triplicate. Graph is representative of three donors